Sundry Photography/iStock Editorial via Getty Images Cytokinetics ( NASDAQ: CYTK ) and Royalty Pharma ( NASDAQ: RPRX ) have expanded their funding collaboration to provide up to $575M, including $250M upfront, to support commercialization of Cytokinetics’ drug aficamten and advancement of its pipeline. Under the deal, Cytokinetics will receive $50M for the commercial launch and draw up to an additional $185M within 12 months of the drug receiving FDA approval for the treatment of obstructive hypertrophic cardiomyopathy, or oHCM. The money will be repayable in over ten years in quarterly installments, according to a statement .

Royalty will also buy $50M of Cytokinetics common stock. The private placement will run concurrent to a $500M underwritten public offering of Cytokinetics common shares, also announced on Wednesday. The deal also restructured Royalty Pharma’s royalty for aficamten, if it is approved.

Royalty will now receive 4.5% on up to $5B in annual net sales and 1% above the $5B mark. Cytokinetics will also receive $100M upfront to fund a confirmatory Phase 3 study of omecamtiv mecarbil in patients with heart failure and reduced ejection fraction.

If the FDA approves the product within certain timeframes, Royalty will receive $100M in payments following the approval, plus an incremental 2% royalty on annual net sales and/or fix payments. If the study fails or the drug is not approved, Cytokinetics will repay Royalty up to $237.5M.

The biotech company will also g.